Equities
  • Price (CHF)549.20
  • Today's Change1.40 / 0.26%
  • Shares traded122.97k
  • 1 Year change+64.23%
  • Beta1.2260
Data delayed at least 15 minutes, as of Nov 08 2024 16:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CHFIncome statement in CHFView more

Year on year Lonza Group AG had net income fall -46.17% from 1.22bn to 654.00m despite a 7.94% increase in revenues from 6.22bn to 6.72bn. An increase in the cost of goods sold as a percentage of sales from 60.82% to 64.18% was a component in the falling net income despite rising revenues.
Gross margin29.21%
Net profit margin8.57%
Operating margin13.05%
Return on assets3.23%
Return on equity5.83%
Return on investment3.81%
More ▼

Cash flow in CHFView more

In 2023, Lonza Group AG increased its cash reserves by 9.63%, or 129.00m. The company earned 1.39bn from its operations for a Cash Flow Margin of 20.66%. In addition the company used 1.10bn on investing activities and also paid 152.00m in financing cash flows.
Cash flow per share15.73
Price/Cash flow per share34.86
Book value per share133.83
Tangible book value per share64.37
More ▼

Balance sheet in CHFView more

Lonza Group AG has a Debt to Total Capital ratio of 28.73%, a higher figure than the previous year's 23.88%.
Current ratio2.04
Quick ratio1.38
Total debt/total equity0.4058
Total debt/total capital0.2873
More ▼

Growth rates in CHF

Year on year, growth in dividends per share increased 14.29% while earnings per share excluding extraordinary items fell by -45.68%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)0.65%
Div growth rate (5 year)7.78%
Payout ratio (TTM)50.34%
EPS growth(5 years)0.2499
EPS (TTM) vs
TTM 1 year ago
-47.86
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.